| CAS NO: | 355025-13-7 |
| 包装 | 价格(元) |
| 10 mM * 1 mL in DMSO | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
| 生物活性 | Ki16198 is a potent and orally activeLPA receptorantagonist, the methyl ester of Ki16425 (HY-13285). Ki16198 inhibits LPA1and LPA3-induced inositol phosphate production with Ki values of 0.34 μM and 0.93 μM, respectively. Ki16198 is effective for pancreaticcancertumorigenesis and metastasis in vivo[1]. | ||||||||||||||||
| IC50& Target | Ki: 0.34 μM (LPA1 receptor)Ki: 0.93 μM (LPA1 receptor)[1] | ||||||||||||||||
| 体外研究 (In Vitro) | Ki16198 (0-10 μM; 48 hours) is effective to inhibit migration and invasion responses to LPA with a potency similar to that of Ki16425. The inhibitory effects Ki16198 on the invasion response to LPA, but not to EGF in several pancreatic cancer cell lines, including Panc-1,CFPAC-1, and BxPC-3 cells[1].Ki16198 (10 μM; 48 hours) signifivcantly decreases expression of proMMP-9 protein and mRNA expression in YAPC-PD cells[1]. | ||||||||||||||||
| 体内研究 (In Vivo) | Ki16198 (oral administaion; 1 mg in 500 ul; 28 days) significantly decreases the degree of metastasis activity in Ki16198-treated mice. Similiar to liver, metastasis to lung and brain in mice is also observed[1].
| ||||||||||||||||
| 分子量 | 488.98 | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| Formula | C24H25ClN2O5S | ||||||||||||||||
| CAS 号 | 355025-13-7 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 溶解性数据 | In Vitro: DMSO : 100 mg/mL(204.51 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
